Is Galectin Therapeutics Stock a Good Investment?
Galectin Therapeutics Investment Advice | GALT |
- Examine Galectin Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Galectin Therapeutics' leadership team and their track record. Good management can help Galectin Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Galectin Therapeutics' business and its evolving consumer preferences.
- Compare Galectin Therapeutics' performance and market position to its competitors. Analyze how Galectin Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Galectin Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Galectin Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Galectin Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Galectin Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Solid | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Galectin Therapeutics Stock
Researching Galectin Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 31.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.73. Galectin Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 23rd of March 2012.
To determine if Galectin Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Galectin Therapeutics' research are outlined below:
| Galectin Therapeutics is way too risky over 90 days horizon | |
| Galectin Therapeutics may become a speculative penny stock | |
| Galectin Therapeutics appears to be risky and price may revert if volatility continues | |
| Galectin Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (41.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galectin Therapeutics currently holds about 15.83 M in cash with (32.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. | |
| Galectin Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Amelio Gilbert F of 50000 shares of Galectin Therapeutics at 1.72 subject to Rule 16b-3 |
Galectin Therapeutics Quarterly Accounts Payable |
|
Galectin Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Galectin Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Galectin Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Galectin Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Galectin Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.2 | -0.18 | 0.02 | 10 | ||
2020-08-10 | 2020-06-30 | -0.09 | -0.11 | -0.02 | 22 | ||
2018-11-13 | 2018-09-30 | -0.09 | -0.07 | 0.02 | 22 | ||
2015-05-11 | 2015-03-31 | -0.2 | -0.22 | -0.02 | 10 | ||
2024-05-15 | 2024-03-31 | -0.16 | -0.19 | -0.03 | 18 | ||
2022-08-15 | 2022-06-30 | -0.19 | -0.16 | 0.03 | 15 | ||
2022-05-16 | 2022-03-31 | -0.14 | -0.17 | -0.03 | 21 | ||
2021-03-31 | 2020-12-31 | -0.16 | -0.13 | 0.03 | 18 |
Know Galectin Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Galectin Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Galectin Therapeutics backward and forwards among themselves. Galectin Therapeutics' institutional investor refers to the entity that pools money to purchase Galectin Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Retirement Guys Formula Llc | 2024-12-31 | 155.3 K | Soltis Investment Advisors, Llc | 2024-12-31 | 140.8 K | Lpl Financial Corp | 2024-12-31 | 138.9 K | Commonwealth Equity Services Inc | 2024-12-31 | 134.5 K | Cambridge Invest Research Advisors, Inc. | 2024-12-31 | 118.6 K | Cutter & Co Brokerage, Inc. | 2024-12-31 | 115.5 K | Charles Schwab Investment Management Inc | 2024-12-31 | 65.1 K | Jpmorgan Chase & Co | 2024-12-31 | 59.7 K | Sanctuary Advisors, Llc | 2024-12-31 | 58.4 K | Vanguard Group Inc | 2024-12-31 | 2.1 M | Blackrock Inc | 2024-12-31 | 1.7 M |
Galectin Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 103.56 M.Market Cap |
|
Galectin Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (3.50) | (3.32) | |
| Return On Assets | (1.31) | (1.38) | |
| Return On Equity | 0.78 | 0.74 |
Determining Galectin Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Galectin Therapeutics is a good buy. For example, gross profit margin measures Galectin Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Galectin Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Galectin Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Galectin Therapeutics. Check Galectin Therapeutics' Beneish M Score to see the likelihood of Galectin Therapeutics' management manipulating its earnings.
Evaluate Galectin Therapeutics' management efficiency
Galectin Therapeutics has return on total asset (ROA) of (0.9672) % which means that it has lost $0.9672 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (37.2795) %, meaning that it created substantial loss on money invested by shareholders. Galectin Therapeutics' management efficiency ratios could be used to measure how well Galectin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.38 in 2025. Return On Capital Employed is likely to gain to -3.32 in 2025. Total Current Liabilities is likely to gain to about 18.9 M in 2025. Liabilities And Stockholders Equity is likely to gain to about 34.1 M in 2025| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.15) | (1.09) | |
| Tangible Book Value Per Share | (1.15) | (1.09) | |
| Enterprise Value Over EBITDA | (831.25) | (789.69) | |
| Price Book Value Ratio | (1.91) | (1.81) | |
| Enterprise Value Multiple | (831.25) | (789.69) | |
| Price Fair Value | (1.91) | (1.81) | |
| Enterprise Value | 99.5 M | 104.5 M |
The decision-making processes within Galectin Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 0.69 |
Basic technical analysis of Galectin Stock
As of the 25th of March, Galectin Therapeutics retains the Market Risk Adjusted Performance of 0.0096, risk adjusted performance of 0.0101, and Downside Deviation of 9.67. Galectin Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Galectin Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Galectin Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Galectin Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Galectin Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Galectin Therapeutics' Outstanding Corporate Bonds
Galectin Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Galectin Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Galectin bonds can be classified according to their maturity, which is the date when Galectin Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ADGLXY 2625 31 MAR 36 Corp BondUS36321PAB67 | View | |
| ADGLXY 175 30 SEP 27 Corp BondUS36321PAA84 | View | |
| ADGLXY 216 31 MAR 34 Corp BondUS36321PAD24 | View | |
| ADGLXY 294 30 SEP 40 Corp BondUS36321PAE07 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Galectin Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Galectin Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0101 | |||
| Market Risk Adjusted Performance | 0.0096 | |||
| Mean Deviation | 4.43 | |||
| Semi Deviation | 8.97 | |||
| Downside Deviation | 9.67 | |||
| Coefficient Of Variation | 79539.6 | |||
| Standard Deviation | 8.62 | |||
| Variance | 74.27 | |||
| Information Ratio | 0.0043 | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | 0.3494 | |||
| Sortino Ratio | 0.0039 | |||
| Treynor Ratio | (0.0004) | |||
| Maximum Drawdown | 57.48 | |||
| Value At Risk | (8.23) | |||
| Potential Upside | 9.48 | |||
| Downside Variance | 93.47 | |||
| Semi Variance | 80.48 | |||
| Expected Short fall | (5.05) | |||
| Skewness | (1.81) | |||
| Kurtosis | 16.97 |
| Risk Adjusted Performance | 0.0101 | |||
| Market Risk Adjusted Performance | 0.0096 | |||
| Mean Deviation | 4.43 | |||
| Semi Deviation | 8.97 | |||
| Downside Deviation | 9.67 | |||
| Coefficient Of Variation | 79539.6 | |||
| Standard Deviation | 8.62 | |||
| Variance | 74.27 | |||
| Information Ratio | 0.0043 | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | 0.3494 | |||
| Sortino Ratio | 0.0039 | |||
| Treynor Ratio | (0.0004) | |||
| Maximum Drawdown | 57.48 | |||
| Value At Risk | (8.23) | |||
| Potential Upside | 9.48 | |||
| Downside Variance | 93.47 | |||
| Semi Variance | 80.48 | |||
| Expected Short fall | (5.05) | |||
| Skewness | (1.81) | |||
| Kurtosis | 16.97 |
Consider Galectin Therapeutics' intraday indicators
Galectin Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Galectin Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 22871.5 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.71 | |||
| Day Typical Price | 1.73 | |||
| Price Action Indicator | 0.07 |
Galectin Stock media impact
Far too much social signal, news, headlines, and media speculation about Galectin Therapeutics that are available to investors today. That information is available publicly through Galectin media outlets and privately through word of mouth or via Galectin internal channels. However, regardless of the origin, that massive amount of Galectin data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Galectin Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Galectin Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Galectin Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Galectin Therapeutics alpha.
Galectin Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Galectin Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Galectin Therapeutics Corporate Management
| CPA CPA | Treasurer CFO | Profile | |
| Khurram MD | Chief Officer | Profile | |
| Jeff Katstra | Head Development | Profile | |
| Robert Tritt | General Counsel | Profile | |
| Beth Knowles | Executive Manager | Profile |
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.